

What is claimed is:




1. The compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof:



(I)



Wherein:

the  in the formula (I) is selected from:









R_{21} is selected from halogen;

R_{22} is selected from hydrogen;

R_3 is selected from ,  or , each hydrogen in the R_3 at each occurrence is independently optionally substituted by 1 R_{31} or 2 R_{31};

Each R_{31} at each occurrence is independently selected from -C_{1-6}alkyl;

R_4 is selected from , each hydrogen in the  is independently optionally substituted with 1 R_{42} or 2 R_{42};

R_{41} is selected from ;


R_{4a}, R_{4b} or R_{4c} is independently selected from hydrogen or halogen;

Each R_{42} at each occurrence is independently selected from -C_{1-6}alkyl or -C_{1-6}alkylene-CN.


2. The compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof according to claim 1, wherein:

R_{21} is selected from -Cl.

3. The compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof according to claim 1 or 2, wherein:


R_3 is selected from .

4. The compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof according to any one of claims 1 to 3, wherein:

R_3 is selected from .

5. The compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof according to any one of claims 1 to 4, wherein:


R_4 is selected from:



6. The compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof according to any one of claims 1 to 5,


wherein:


R_4 is selected from:





7. A compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof, wherein:


the compound is selected from:




































, ,  or .

8. The compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof according to any one of claims 1 to 7, wherein:

the compound is selected from:


  or .

9. A pharmaceutical composition comprising the compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof according to any one of claims 1 to 8, and at least one pharmaceutically acceptable excipient.

10. Use of the compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof according to any one of claims 1 to 8; or the pharmaceutical composition according to claim 9 in the manufacture of a medicament for the treatment of cancer related to KRAS G12C mutant protein.


11. The use according to claim 10, wherein,

the compound of formula (I) has the following formula:

;

the pharmaceutical composition comprises the compound of formula (I), the stereoisomer thereof, the atropisomer thereof, the pharmaceutically acceptable salt thereof, the pharmaceutically acceptable salt


of the stereoisomer thereof or the pharmaceutically acceptable salt of the atropisomer thereof, and at least one pharmaceutically acceptable excipient, wherein the compound has the following structure:



12. The use according to claim 10 or 11, wherein the cancer is selected from blood cancer, pancreatic cancer, colon cancer, rectal cancer, colorectal cancer or lung cancer,

wherein the blood cancer is selected from acute myeloid leukemia or acute lymphocytic leukemia; the lung cancer is selected from non-small cell lung cancer or small cell lung cancer.

13. An intermediate selected from:



14. The compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of the atropisomer thereof according to any one of claims 1 to 8; or the pharmaceutical composition according to claim 9 for use in therapy.